Saturday, 31 October 2026European Markets

GYLDENDAL Stock Was 10% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with GYLDENDAL (GYL.OL) jumping 10% to kr550.00 on Wednesday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.01% to kr1,281.17, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

About GYLDENDAL

Gyldendal ASA, through its subsidiaries, publishes and sells books in Norway. The company also publishes and produces content, including learning materials for kindergarten, primary school, upper secondary school, students, and professional market; and sells audiobooks and other goods, as well as provides streaming services. It operates bookstores and an online bookstore. The company was founded in 1925 and is headquartered in Oslo, Norway. Gyldendal ASA operates as a subsidiary of Erik Must AS.

Earnings Per Share

As for profitability, GYLDENDAL has a trailing twelve months EPS of kr5.4.

PE Ratio

GYLDENDAL has a trailing twelve months price to earnings ratio of 101.85. Meaning, the purchaser of the share is investing kr101.85 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for GYLDENDAL is 1 which is 87.5% below its average volume of 8.

More news about GYLDENDAL (GYL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com